In Vivo Evaluation of Transdermal Iodide Microemulsion for Treating Iodine Deficiency Using Sprague Dawley Rats

Alaadin Alayoubi, Ryan D. Sullivan, Hao Lou, Hemlata Patel, Timothy Mandrell, Richard Helms, Hassan Almoazen

Research output: Contribution to journalArticle

Abstract

The objective of this study was to evaluate the transdermal efficiency of iodide microemulsion in treating iodine deficiency using rats as an animal model. Animals were fed either iodine-deficient diet (20 μg/kg iodide) or control diet (200 μg/kg iodide) over a 17-month period. At month 14, iodide microemulsion was applied topically in iodine-deficient group and physiological evaluations of thyroid gland functions were characterized by monitoring the thyroid hormones (T3, T4), thyroid-stimulating hormone (TSH), iodide ion excretion in urine, and the overall rat body weights in both groups. Moreover, morphological evaluations of thyroid gland before and after treatment were performed by ultrasound imaging and through histological assessment. Prior to microemulsion treatment, the levels of T3, T4, and TSH in iodine-deficient group were statistically significant as compared to that in the control group. The levels of T3 and T4 increased while TSH level decreased significantly in iodine-deficient group within the first 4 weeks of treatment. After treatment, iodide concentration in urine increased significantly. There was no statistical difference in weight between the two groups. Ultrasound imaging and histological evaluations showed evidence of hyperplasia in iodine-deficient group. Topical iodide microemulsion has shown a promising potential as a novel delivery system to treat iodine deficiency.

Original languageEnglish (US)
Pages (from-to)618-630
Number of pages13
JournalAAPS PharmSciTech
Volume17
Issue number3
DOIs
StatePublished - Jan 1 2016

Fingerprint

iodine deficiency
Iodides
iodides
Iodine
Sprague Dawley Rats
iodine
rats
thyrotropin
L-thyroxine
triiodothyronine
Thyrotropin
thyroid gland
Thyroxine
ultrasonography
Ultrasonography
Thyroid Gland
urine
Urine
Diet
Triiodothyronine

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

Cite this

In Vivo Evaluation of Transdermal Iodide Microemulsion for Treating Iodine Deficiency Using Sprague Dawley Rats. / Alayoubi, Alaadin; Sullivan, Ryan D.; Lou, Hao; Patel, Hemlata; Mandrell, Timothy; Helms, Richard; Almoazen, Hassan.

In: AAPS PharmSciTech, Vol. 17, No. 3, 01.01.2016, p. 618-630.

Research output: Contribution to journalArticle

Alayoubi, Alaadin ; Sullivan, Ryan D. ; Lou, Hao ; Patel, Hemlata ; Mandrell, Timothy ; Helms, Richard ; Almoazen, Hassan. / In Vivo Evaluation of Transdermal Iodide Microemulsion for Treating Iodine Deficiency Using Sprague Dawley Rats. In: AAPS PharmSciTech. 2016 ; Vol. 17, No. 3. pp. 618-630.
@article{348a0838a46b4081b38cab1acda98f5f,
title = "In Vivo Evaluation of Transdermal Iodide Microemulsion for Treating Iodine Deficiency Using Sprague Dawley Rats",
abstract = "The objective of this study was to evaluate the transdermal efficiency of iodide microemulsion in treating iodine deficiency using rats as an animal model. Animals were fed either iodine-deficient diet (20 μg/kg iodide) or control diet (200 μg/kg iodide) over a 17-month period. At month 14, iodide microemulsion was applied topically in iodine-deficient group and physiological evaluations of thyroid gland functions were characterized by monitoring the thyroid hormones (T3, T4), thyroid-stimulating hormone (TSH), iodide ion excretion in urine, and the overall rat body weights in both groups. Moreover, morphological evaluations of thyroid gland before and after treatment were performed by ultrasound imaging and through histological assessment. Prior to microemulsion treatment, the levels of T3, T4, and TSH in iodine-deficient group were statistically significant as compared to that in the control group. The levels of T3 and T4 increased while TSH level decreased significantly in iodine-deficient group within the first 4 weeks of treatment. After treatment, iodide concentration in urine increased significantly. There was no statistical difference in weight between the two groups. Ultrasound imaging and histological evaluations showed evidence of hyperplasia in iodine-deficient group. Topical iodide microemulsion has shown a promising potential as a novel delivery system to treat iodine deficiency.",
author = "Alaadin Alayoubi and Sullivan, {Ryan D.} and Hao Lou and Hemlata Patel and Timothy Mandrell and Richard Helms and Hassan Almoazen",
year = "2016",
month = "1",
day = "1",
doi = "10.1208/s12249-015-0392-z",
language = "English (US)",
volume = "17",
pages = "618--630",
journal = "AAPS PharmSciTech",
issn = "1530-9932",
publisher = "American Association of Pharmaceutical Scientists",
number = "3",

}

TY - JOUR

T1 - In Vivo Evaluation of Transdermal Iodide Microemulsion for Treating Iodine Deficiency Using Sprague Dawley Rats

AU - Alayoubi, Alaadin

AU - Sullivan, Ryan D.

AU - Lou, Hao

AU - Patel, Hemlata

AU - Mandrell, Timothy

AU - Helms, Richard

AU - Almoazen, Hassan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The objective of this study was to evaluate the transdermal efficiency of iodide microemulsion in treating iodine deficiency using rats as an animal model. Animals were fed either iodine-deficient diet (20 μg/kg iodide) or control diet (200 μg/kg iodide) over a 17-month period. At month 14, iodide microemulsion was applied topically in iodine-deficient group and physiological evaluations of thyroid gland functions were characterized by monitoring the thyroid hormones (T3, T4), thyroid-stimulating hormone (TSH), iodide ion excretion in urine, and the overall rat body weights in both groups. Moreover, morphological evaluations of thyroid gland before and after treatment were performed by ultrasound imaging and through histological assessment. Prior to microemulsion treatment, the levels of T3, T4, and TSH in iodine-deficient group were statistically significant as compared to that in the control group. The levels of T3 and T4 increased while TSH level decreased significantly in iodine-deficient group within the first 4 weeks of treatment. After treatment, iodide concentration in urine increased significantly. There was no statistical difference in weight between the two groups. Ultrasound imaging and histological evaluations showed evidence of hyperplasia in iodine-deficient group. Topical iodide microemulsion has shown a promising potential as a novel delivery system to treat iodine deficiency.

AB - The objective of this study was to evaluate the transdermal efficiency of iodide microemulsion in treating iodine deficiency using rats as an animal model. Animals were fed either iodine-deficient diet (20 μg/kg iodide) or control diet (200 μg/kg iodide) over a 17-month period. At month 14, iodide microemulsion was applied topically in iodine-deficient group and physiological evaluations of thyroid gland functions were characterized by monitoring the thyroid hormones (T3, T4), thyroid-stimulating hormone (TSH), iodide ion excretion in urine, and the overall rat body weights in both groups. Moreover, morphological evaluations of thyroid gland before and after treatment were performed by ultrasound imaging and through histological assessment. Prior to microemulsion treatment, the levels of T3, T4, and TSH in iodine-deficient group were statistically significant as compared to that in the control group. The levels of T3 and T4 increased while TSH level decreased significantly in iodine-deficient group within the first 4 weeks of treatment. After treatment, iodide concentration in urine increased significantly. There was no statistical difference in weight between the two groups. Ultrasound imaging and histological evaluations showed evidence of hyperplasia in iodine-deficient group. Topical iodide microemulsion has shown a promising potential as a novel delivery system to treat iodine deficiency.

UR - http://www.scopus.com/inward/record.url?scp=84939642226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939642226&partnerID=8YFLogxK

U2 - 10.1208/s12249-015-0392-z

DO - 10.1208/s12249-015-0392-z

M3 - Article

VL - 17

SP - 618

EP - 630

JO - AAPS PharmSciTech

JF - AAPS PharmSciTech

SN - 1530-9932

IS - 3

ER -